Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Kymera Therapeutics ( (KYMR) ) just unveiled an announcement.
On June 2, 2025, Kymera Therapeutics announced positive results from their Phase 1 healthy volunteer study of KT-621, an oral STAT6 degrader aimed at treating immuno-inflammatory diseases. The study demonstrated robust STAT6 degradation in blood and skin, with a favorable safety profile comparable to placebo, and showed potential for KT-621 to be a transformative treatment for Th2 diseases. The company plans to advance KT-621 into Phase 1b and Phase 2b trials for atopic dermatitis and asthma, respectively, in late 2025 and early 2026.
The most recent analyst rating on (KYMR) stock is a Buy with a $46.00 price target. To see the full list of analyst forecasts on Kymera Therapeutics stock, see the KYMR Stock Forecast page.
Spark’s Take on KYMR Stock
According to Spark, TipRanks’ AI Analyst, KYMR is a Neutral.
Kymera Therapeutics shows a blend of strengths and challenges typical of a biotech firm. Strong equity and strategic pipeline advancements are offset by declining revenue and cash flow difficulties. Technical signals are mixed, and the valuation is unattractive due to negative earnings. The overall score reflects these mixed indicators, with positive guidance from the earnings call providing some optimism.
To see Spark’s full report on KYMR stock, click here.
More about Kymera Therapeutics
Kymera Therapeutics is a clinical-stage biotechnology company focused on developing oral small molecule degrader medicines targeting immunological diseases.
Average Trading Volume: 717,224
Technical Sentiment Signal: Sell
Current Market Cap: $1.93B
For an in-depth examination of KYMR stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue